// AST – IMS - [DMinute_ROS]

Inca Investments Has Upped Copa Holdings (CPA) Stake By $504,000; Snyder Capital Management LP Boosted By $373,616 Its Halozyme Therapeutics (HALO) Holding

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Logo

Snyder Capital Management LP increased Halozyme Therapeutics Inc. (HALO) stake by 0.99% reported in 2018Q2 SEC filing. Snyder Capital Management LP acquired 23,351 shares as Halozyme Therapeutics Inc. (HALO)’s stock declined 9.63%. The Snyder Capital Management LP holds 2.38 million shares with $40.08 million value, up from 2.35M last quarter. Halozyme Therapeutics Inc. now has $2.21B valuation. The stock decreased 7.12% or $1.18 during the last trading session, reaching $15.4. About 868,192 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 32.24% since December 5, 2017 and is uptrending. It has outperformed by 16.62% the S&P500. Some Historical HALO News: 16/05/2018 – Merck:Evidence Continues to Support the Role of KEYTRUDA as a Foundational Treatment for Many Types of Cancer; 18/05/2018 – FDA – MERCK, GENENTECH HAVE STOPPED ENROLLING PATIENTS WHOSE TUMORS HAVE PD-L1 LOW STATUS TO KEYTRUDA/TECENTRIQ MONOTHERAPY ARMS PER DMCS’ RECOMMENDATIONS; 13/03/2018 – MERCK & CO INC – SBLA FOR KEYTRUDA IS BASED IN PART ON DATA FROM PHASE 2 KEYNOTE-158 TRIAL; 10/05/2018 – GENENTECH PROVIDES UPDATE ON PHASE lll STUDY OF TECENTRIQ (ATEZOLIZUMAB) AND COTELLIC (COBIMETINIB) IN PEOPLE WITH HEAVILY PRE-TREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER; 16/04/2018 – Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell; 18/05/2018 – FDA Warns of Decreased Survival in Keytruda, Tecentriq Trials; 07/03/2018 – MERCK & CO – CO, ISAI TO DEVELOP AND COMMERCIALIZE LENVIMA JOINTLY, BOTH AS MONOTHERAPY AND IN COMBINATION WITH MERCK’S ANTI-PD-1 THERAPY, KEYTRUDA; 09/04/2018 – Merck: Keytruda Monotherapy Meets Primary Endpoint in Phase 3 Study; 30/04/2018 – FDA GRANTS PRIORITY REVIEW TO MERCK’S SBLA FOR KEYTRUDA®; 23/04/2018 – EUROPEAN MEDICINES AGENCY VALIDATES TYPE Il VARIATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY AS FIRST-LINE THERAPY IN METASTATIC

Inca Investments Llc increased Copa Holdings (CPA) stake by 1.61% reported in 2018Q2 SEC filing. Inca Investments Llc acquired 4,500 shares as Copa Holdings (CPA)’s stock declined 25.43%. The Inca Investments Llc holds 284,200 shares with $32.07M value, up from 279,700 last quarter. Copa Holdings now has $3.55 billion valuation. The stock decreased 4.57% or $4.01 during the last trading session, reaching $83.65. About 508,244 shares traded. Copa Holdings, S.A. (NYSE:CPA) has declined 42.26% since December 5, 2017 and is downtrending. It has underperformed by 57.88% the S&P500. Some Historical CPA News: 10/05/2018 – COPA AIRLINES TO RESTORE MORE VENEZUELA FLIGHTS BY END MAY; 11/04/2018 – Copa Holdings: March Revenue Passenger Miles Up 10.4; 14/05/2018 – COPA HOLDINGS APRIL TRAFFIC UP 11.9% Y/Y; 28/03/2018 – City of Chicago: Mayor Emanuel Accepts COPA Search Committee’s Unanimous Recommendation for New Chief Administrator; 22/05/2018 – James and Molli Martin of the Sunshine Mill and Copa Di Vino Celebrate the Eighth Year Anniversary of Their Urban Renewal Project in The Dalles, Oregon; 11/04/2018 – COPA HOLDINGS SA – FOR MONTH OF MARCH 2018, COPA HOLDINGS’ SYSTEM-WIDE PASSENGER TRAFFIC (RPMS) INCREASED 15.3% YEAR OVER YEAR; 14/05/2018 – COPA HOLDINGS SA – APRIL 2018 RPM 1,712.5 MLN, UP 11.9 PCT; 20/03/2018 – Minor League Baseball Unveils On-Field Brands for “Copa de la Diversión”; 24/05/2018 – COPA HOLDINGS SA CPA.N : UBS RAISES TO BUY FROM SELL; 05/04/2018 – Venezuela halts commercial ties with Panama, suspends Copa flights

Among 3 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Halozyme Therapeutics had 4 analyst reports since August 8, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) on Monday, November 26 with “Buy” rating. JMP Securities maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating on Tuesday, November 27. JMP Securities has “Buy” rating and $2100 target. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Market Perform” rating by BMO Capital Markets on Wednesday, August 8.

Snyder Capital Management LP decreased Src Energy Inc. stake by 355,448 shares to 2.10M valued at $23.11M in 2018Q2. It also reduced Omnicell Inc. (NASDAQ:OMCL) stake by 99,199 shares and now owns 109,113 shares. Teledyne Inc. (NYSE:TDY) was reduced too.

Investors sentiment decreased to 0.95 in Q2 2018. Its down 0.56, from 1.51 in 2018Q1. It is negative, as 25 investors sold HALO shares while 59 reduced holdings. 25 funds opened positions while 55 raised stakes. 118.72 million shares or 0.69% less from 119.54 million shares in 2018Q1 were reported. Moreover, Swiss Commercial Bank has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Morgan Stanley invested in 0% or 892,403 shares. Invesco owns 4.07 million shares. Landscape Ltd Company owns 0.02% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 11,146 shares. State Common Retirement Fund invested in 0.02% or 916,884 shares. Credit Suisse Ag invested in 110,829 shares or 0% of the stock. Advisory Svcs Ntwk Lc reported 812 shares. Torray Limited Co owns 37,552 shares. Bluemountain Cap Management Ltd Llc invested in 50,647 shares. Macquarie Gp Ltd holds 500,000 shares or 0.01% of its portfolio. First Light Asset Management Ltd Llc holds 889,729 shares. Moreover, Alps has 0.02% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Grp One Trading LP has invested 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Great West Life Assurance Can invested in 0% or 14,291 shares. Nuveen Asset Ltd Liability invested in 22,883 shares.

More notable recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: Nasdaq.com which released: “Health Care Sector Update for 11/27/2018: HALO,GTHX,ACAD – Nasdaq” on November 27, 2018, also Nasdaq.com with their article: “Halo Labs: Improving Investor Reach, Transparency, and Liquidity — CFN Media – Nasdaq” published on November 21, 2018, Seekingalpha.com published: “Halozyme: Explaining The Change In Trial Design – Seeking Alpha” on November 30, 2018. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) were released by: Nasdaq.com and their article: “PVH Stock Down 16% in 3 Months: Can It Reverse the Trend? – Nasdaq” published on December 04, 2018 as well as Nasdaq.com‘s news article titled: “Report: Exploring Fundamental Drivers Behind Entergy, BLACKLINE INC, HollyFrontier, Hill-Rom, Apache, and Halozyme Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments – Nasdaq” with publication date: November 08, 2018.

More notable recent Copa Holdings, S.A. (NYSE:CPA) news were published by: Seekingalpha.com which released: “Copa Holdings, S.A. (CPA) CEO Pedro Heilbron on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” on November 15, 2018, also Fool.com with their article: “Fuel Costs Sink Copa Holdings’ Earnings – The Motley Fool” published on November 21, 2018, 247Wallst.com published: “Top Analyst Upgrades and Downgrades: ArcelorMittal, Barclays, Cree, Ctrip.com, Michael Kors, PVH, Skyworks, TripAdvisor, YRC Worldwide, Yelp and More – 24/7 Wall St.” on November 09, 2018. More interesting news about Copa Holdings, S.A. (NYSE:CPA) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For November 15, 2018 – Benzinga” published on November 15, 2018 as well as Gurufocus.com‘s news article titled: “Copa Holdings Announces Monthly Traffic Statistics For October 2018 – GuruFocus.com” with publication date: November 14, 2018.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.